Allianz Asset Management GmbH acquired a new position in shares of Hutchison China MediTech Ltd – (NASDAQ:HCM) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 175,300 shares of the company’s stock, valued at approximately $6,910,000. Allianz Asset Management GmbH owned 0.13% of Hutchison China MediTech at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of HCM. Comerica Bank purchased a new position in Hutchison China MediTech in the 3rd quarter valued at $203,000. Perceptive Advisors LLC purchased a new position in Hutchison China MediTech in the 3rd quarter valued at $273,000. Mckinley Capital Management LLC Delaware purchased a new position in Hutchison China MediTech in the 4th quarter valued at $1,237,000. Wells Fargo & Company MN purchased a new position in Hutchison China MediTech in the 4th quarter valued at $1,340,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in Hutchison China MediTech in the 4th quarter valued at $10,334,000. 7.46% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have weighed in on the company. BidaskClub lowered Hutchison China MediTech from a “buy” rating to a “hold” rating in a report on Tuesday, March 20th. Zacks Investment Research lowered Hutchison China MediTech from a “hold” rating to a “sell” rating in a report on Thursday, March 15th.
Shares of HCM traded down $0.24 during midday trading on Friday, reaching $29.67. The company had a trading volume of 36,543 shares, compared to its average volume of 74,484. Hutchison China MediTech Ltd – has a 1-year low of $18.00 and a 1-year high of $42.25. The company has a market capitalization of $3,976.59, a PE ratio of -134.86 and a beta of 0.40.
TRADEMARK VIOLATION WARNING: “Allianz Asset Management GmbH Takes $6.91 Million Position in Hutchison China MediTech Ltd – (HCM)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/07/allianz-asset-management-gmbh-takes-6-91-million-position-in-hutchison-china-meditech-ltd-hcm.html.
Hutchison China MediTech Company Profile
Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments.
Receive News & Ratings for Hutchison China MediTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech and related companies with MarketBeat.com's FREE daily email newsletter.